AI helper
This is a Request for Information (RFI) issued by the Department of Veterans Affairs (VA), VISN 22 Network Contracting Office, for in vitro diagnostic substances, reagents, test kits, and sets. The purpose is for information and planning, not a solicitation. They are seeking information on potential qualified sources for MSI testing reagent cartridges and reagent rental for in-house single gene molecular testing. The assay must be fully automated, ready-to-use, provide results in approximately 150 minutes, require no sample extraction, and test a minimum of 1 slice of FFPE tissue. It should also eliminate the use of external quality control and qualitatively detect mutations in 7 novel MSI loci. Responders must provide company name, address, point of contact, business size status, NAICS code applicability, manufacturer/distributor information, country of origin, FSS/GSA/SEWP contract details if applicable, general pricing, and capabilities demonstrating that equal-to items meet all salient characteristics. Responses must be submitted via email to ***@***. *. * no later than Thursday, April 23, 2026, by 1:00 PM Pacific Time. Telephone responses will not be accepted. This RFI is not a solicitation, and responses do not guarantee inclusion in future solicitations.
The responses to this notice must be received no later than Thursday, April 23, 2026, by 1:00 p. m. Pacific Time.
The Department of Veterans Affairs is seeking sources that can provide MSI testing reagent cartridges as reagent rental needed to perform in-house single gene molecular testing that at a minimum meets the following salient characteristics with a brand name or equal product for the VA Greater Los Angeles Healthcare System: the assay shall be fully automated, ready to made reagent with no reagent preparation required, provide a result in approximately 150 minutes, no sample extraction required prior to use, testing volume that can be performed on a minimum of 1 slice of FFPE tissue section, eliminate use of external quality control, and qualitative detection of mutations in 7 novel MSI loci ACVR2A, BTBD7, DIDO1, MRE11, RYR3, SEC31A, and SULF2.